Latest Ratios: P/E Ratio 2.0x · EV/EBITDA 8.4x · ROE -5.4%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $123M | $259M | $172M | $107M | $331M | $684M | $245M | $593M | — | — | — |
| Enterprise Value | $110M | $240M | $70M | $78M | $265M | $634M | $338M | $595M | — | — | — |
| P/E Ratio → | 1.95 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.56 | 1.39 | 1.08 | 0.72 | 2.27 | 8.64 | 2.82 | 7.38 | — | — | — |
| P/B Ratio | 0.45 | 0.74 | 0.56 | 0.40 | 0.65 | 1.43 | 0.82 | 1.81 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 44.55 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.29 | 0.44 | 0.52 | 1.82 | 8.01 | 3.90 | 7.40 | — | — | — |
| EV / EBITDA | 8.41 | — | — | — | — | — | — | 41.37 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 156.95 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.7% | 3.7% | 29.7% | 23.5% | 21.7% | -35.9% | -65.1% | 60.3% | -215.4% | -61.2% | 86.7% |
| Operating Margin | -34.1% | -34.1% | -21.7% | -162.7% | -26.6% | -92.0% | -167.6% | 6.8% | 293.0% | -206.0% | 20.3% |
| Net Profit Margin | -9.6% | -9.6% | -28.4% | -153.8% | -9.8% | -165.1% | -156.9% | -11.9% | 165.0% | -202.1% | 13.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.4% | -5.4% | -15.7% | -58.9% | -2.9% | -33.5% | -43.5% | -3.7% | 15.3% | -17.1% | 3.2% |
| ROA | -3.7% | -3.7% | -12.9% | -52.4% | -2.5% | -26.4% | -31.5% | -2.6% | 10.4% | -14.8% | 2.5% |
| ROIC | -17.8% | -17.8% | -11.7% | -53.1% | -6.7% | -13.3% | -30.2% | 1.5% | 17.4% | -13.2% | 3.5% |
| ROCE | -16.0% | -16.0% | -11.0% | -60.8% | -7.4% | -15.6% | -36.8% | 1.6% | 19.3% | -16.1% | 3.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | 0.39 | 0.15 | 0.54 | 0.04 | 0.17 |
| Debt / EBITDA | — | — | — | — | — | — | — | 3.45 | 2.48 | — | 3.69 |
| Net Debt / Equity | — | -0.06 | -0.33 | -0.11 | -0.13 | -0.10 | 0.31 | 0.01 | 0.24 | 0.02 | -0.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.14 | 1.10 | — | -1.16 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -32.50 | -43.16 | -23.41 | 0.39 | 3.75 | -39.96 | 2.94 |
Net cash position: cash ($28M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | 2.26 | 4.92 | 6.95 | 4.01 | 9.92 | 5.85 | 4.47 | 18.06 | 6.72 | 16.62 |
| Quick Ratio | 1.28 | 1.28 | 3.37 | 3.34 | 2.77 | 8.06 | 3.39 | 1.88 | 12.30 | 5.91 | 14.04 |
| Cash Ratio | 0.23 | 0.23 | 2.02 | 1.51 | 1.78 | 6.99 | 2.57 | 1.09 | 11.56 | 5.11 | 13.34 |
| Asset Turnover | — | 0.33 | 0.39 | 0.50 | 0.25 | 0.14 | 0.20 | 0.19 | 0.04 | 0.06 | 0.11 |
| Inventory Turnover | 1.45 | 1.45 | 1.36 | 1.41 | 1.67 | 2.20 | 2.00 | 0.28 | -0.60 | 1.61 | 0.13 |
| Days Sales Outstanding | — | 127.21 | 84.84 | 67.17 | 116.08 | 98.14 | 71.39 | 52.80 | 23.29 | 68.20 | 93.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 51.3% | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $128M | $95M | $81M | $77M | $64M | $49M | $35M | $32M | $24M | $15M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OGI stock.
Organigram Global Inc.'s current P/E ratio is 2.0x. This places it at the 50th percentile of its historical range.
Organigram Global Inc.'s current EV/EBITDA is 8.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 41.4x.
Organigram Global Inc.'s return on equity (ROE) is -5.4%. The historical average is -35.3%.
Based on historical data, Organigram Global Inc. is trading at a P/E of 2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Organigram Global Inc. has 3.7% gross margin and -34.1% operating margin.
Key Metrics
Top Statement Risk
Persistent Negative Free Cash Flow
Multiples Reflect Earnings Noise, Not Value
Based on reported figures, OGI trades at a P/B of 0.45 and P/S of 0.93, while trailing P/E of -8.80 is not meaningful, suggesting the market prices the equity below book value and below sales.
The sub-1.0 price-to-book ratio implies investors assign little value to the $556.5M equity base, which the prior balance sheet analysis showed rests heavily on acquisition goodwill and capital contributions against a retained deficit of -$484.1M. The forward P/E of 1.55 versus the negative trailing figure indicates the market expects a sharp earnings swing, but this expectation rests on a single profitable quarter in 2026Q3. Investors should monitor whether the forward multiple holds once quarterly profitability normalizes.
Gross Margin Recovers, Operating Margin Lags
As reported in OGI's ratio series, gross margin rose to 39.2% in 2026Q3 from 27.4% in 2026Q2, yet operating margin of 5.0% and net margin of 99.8% diverge sharply, indicating earnings quality concerns.
The gap between the 39.2% gross margin and the 5.0% operating margin reflects a persistent SG&A burden that the prior income statement analysis linked to operating costs not scaling reliably with revenue. The 99.8% net margin is a non-operating artifact rather than evidence of earning power, consistent with the prior finding that net income of $105.5M far exceeded operating income of $5.3M. Operating margin, not net margin, better reflects underlying profitability and remains positive in only a minority of recent quarters.
Low Debt Masks Thin Interest Coverage
Based on OGI's reported figures, debt-to-equity of 0.04 and debt-to-EBITDA of 1.30 indicate minimal leverage, although interest coverage is available in only a few quarters, limiting trend assessment.
Low leverage ratios suggest debt service is not a near-term pressure, consistent with total debt of $21.0M against $556.5M of equity. However, interest coverage data is missing in most periods, so the ability to service debt through operating earnings cannot be confirmed across the cycle. Investors should treat the solvency picture as comfortable on reported figures while recognizing that the operating earnings base supporting coverage has been volatile.
Current Ratio Flatters Thin Cash Position
According to reported balance sheet figures, OGI's current ratio of 2.61 and quick ratio of 1.07 in 2026Q3 look adequate, but cash of $10.9M against persistent negative free cash flow suggests limited stress tolerance.
The quick ratio falling from 3.37 in 2024Q4 to 1.07 in 2026Q3 indicates that current assets have shifted toward inventory and receivables, which the prior balance sheet analysis noted may not be readily convertible. With free cash flow margins negative in most quarters, the cash buffer would likely be consumed quickly under a stress scenario. Investors should monitor cash burn relative to the $10.9M cash balance rather than relying on the headline current ratio.
Efficiency Metrics Mislead on Cash Conversion
Based on reported ratios, OGI's cash conversion cycle of 151 days in 2026Q3 appears manageable, but the cycle has ranged from 137 to 212 days, and asset turnover is not consistently reported, limiting reliable efficiency inference.
The cash conversion cycle is most commonly misapplied to this business model because a shortening cycle in a quarter with acquisition-driven balance sheet changes can reflect reclassified working capital rather than genuine operational improvement. Days inventory outstanding of 212 days in 2026Q3 is elevated and suggests slow-moving stock that may tie up cash. A more informative adjustment would be to track free cash flow conversion against net income, which the prior cash flow analysis showed to be deeply negative at an OCF/NI ratio of -0.04.